Kakkis Emil D

President & CEO, DirectorUltragenyx Pharmaceutical Inc. (RARE) · full profile →Form 4 · filed Mar 4, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$4.2M
Net Open-Market Flow
-$4.2M
Transactions
5
4 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 3, 2025Sell(S)73K$42.10$3.1M642K
Mar 1, 2025Grant(A)107K$0715K
Mar 1, 2025Grant(A)43K$0608K
Feb 28, 2025Sell(S)25K$42.48$1.1M2.2M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 1, 2025Grant(A)78K$078K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-032779) within minutes of acceptance. Every field above traces to the original document. Verify it directly: